

**NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE**

**Single Technology Appraisal**

**Oveporexton for treating type 1 narcolepsy ID6622**

**Provisional Stakeholder List**

<b>Provisional Consultees</b>	<b>Provisional Commentators (no right to submit or appeal)</b>
<p><u>Company</u></p> <ul style="list-style-type: none"> <li>• Takeda (oveporexton)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• Asthma &amp; Lung UK</li> <li>• Brain and Spine Foundation</li> <li>• Brain Charity</li> <li>• British Sleep Society</li> <li>• Narcolepsy UK</li> <li>• Neurological Alliance</li> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> <li>• Sleep Charity</li> </ul> <p><u>Healthcare professional groups</u></p> <ul style="list-style-type: none"> <li>• Association for British Neurologists</li> <li>• Association for Respiratory Technology and Physiology</li> <li>• Association of Respiratory Nurses</li> <li>• British Geriatrics Society</li> <li>• British Neuropathological Society</li> <li>• British Thoracic Society</li> <li>• Interstitial Lung Diseases Interdisciplinary Network</li> <li>• National Heart and Lung Institute</li> <li>• National Neurosciences Advisory Group</li> <li>• Primary Care and Community Neurology Society</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians</li> <li>• Royal Pharmaceutical Society</li> <li>• Royal Society of Medicine</li> <li>• Sleep Matters Medical Advisory Service</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>• All Wales Therapeutics and Toxicology Centre</li> <li>• Allied Health Professionals Federation</li> <li>• Board of Community Health Councils in Wales</li> <li>• British National Formulary</li> <li>• Care Quality Commission</li> <li>• Department of Health - Northern Ireland</li> <li>• Healthcare Improvement Scotland</li> <li>• Medicines and Healthcare products Regulatory Agency</li> <li>• National Association of Primary Care</li> <li>• National Pharmacy Association</li> <li>• Neurological Alliance of Scotland</li> <li>• NHS Confederation</li> <li>• NHS Wales Joint Commissioning Committee</li> <li>• Scottish Medicines Consortium</li> <li>• Wales Neurological Alliance</li> <li>• Welsh Government</li> </ul> <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> <li>• ADVANZ Pharma (venlafaxine)</li> <li>• AS Kalceks (sodium oxybate)</li> <li>• Aspire Pharma (venlafaxine)</li> <li>• Atnahs Pharma (solriamfetol)</li> <li>• Aurobindo Pharma (modafinil, venlafaxine)</li> <li>• Bioprojet (pitolisant)</li> <li>• Brown &amp; Burk (dexamfetamine)</li> <li>• Dexcel Pharma (venlafaxine)</li> <li>• Exeltis (methylphenidate)</li> <li>• Flynn Pharma (methylphenidate)</li> <li>• Genus Pharmaceuticals (venlafaxine)</li> <li>• InfectoPharm (methylphenidate)</li> <li>• Janssen-Cilag (methylphenidate)</li> </ul>

Provisional stakeholder list for the evaluation of oveporexton for treating type 1 narcolepsy ID6622  
Issue date: April 2026

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> <li>• UK Clinical Pharmacy Association</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Department of Health and Social Care</li> <li>• NHS England</li> </ul>	<ul style="list-style-type: none"> <li>• Krka (venlafaxine)</li> <li>• Laboratorios Liconsa (methylphenidate)</li> <li>• Martindale Pharma (methylphenidate, venlafaxine)</li> <li>• Medice (dexamfetamine, methylphenidate)</li> <li>• Morningside Healthcare (venlafaxine)</li> <li>• Neuraxpharm (methylphenidate)</li> <li>• Ranbaxy (venlafaxine)</li> <li>• Reig Jofre (sodium oxybate)</li> <li>• Rosemont Pharmaceuticals (dexamfetamine, venlafaxine)</li> <li>• Sandoz (methylphenidate)</li> <li>• Sovereign Medical (dexamfetamine, venlafaxine)</li> <li>• Strides Pharma (methylphenidate)</li> <li>• Takeda (lisdexamfetamine, methylphenidate)</li> <li>• Teva Pharma (modafinil)</li> <li>• UCB Pharma (sodium oxybate)</li> <li>• Viatrix (clomipramine, methylphenidate, venlafaxine)</li> <li>• Zentiva (methylphenidate)</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• Brain Research UK</li> <li>• British Association for Lung Research</li> <li>• Cochrane Airways Group</li> <li>• Cochrane Multiple Sclerosis and Rare Diseases of the Central Nervous System Group</li> <li>• Genomics England</li> <li>• Institute of Neurology and Neurosurgery</li> <li>• Loughborough University Sleep Research Centre</li> <li>• MRC Clinical Trials Unit</li> <li>• National Institute for Health Research</li> <li>• Sleep Assessment and Advisor Service</li> </ul> <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> <li>• Public Health Wales</li> <li>• UK Health Security Agency</li> </ul>

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected

characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

### **Definitions:**

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

#### Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

#### Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.